Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Daily News

Aspirin as Standalone Stroke Protection Still Overused for Patients With A-fib

Todd Neale

June 27, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

Aspirin Hypersensitivity Can be Managed in PCI Patients Without Switching Drugs

Todd Neale

January 20, 2016

News Conference News AHA 2015

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

Todd Neale

November 10, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

Registro del CORONOR: Warfarin a Largo Plazo + Agente Antiplaquetario Aumenta las Hemorragias en Pacientes con EAC Estable

L.A. McKeown

October 03, 2014

News Daily News

CORONOR Registry: Long-term Warfarin Plus Antiplatelet Increases Bleeding in Stable CAD Patients

L.A. McKeown

October 03, 2014

Presentation

Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD

Presenter: M. Hanon

September 30, 2014

News Daily News

High Reactivity on Aspirin Just Before PCI Linked to Worse Outcomes

September 02, 2014

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Daily News

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

Caitlin E. Cox

October 04, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

News Daily News

El Control del Factor de Riesgo se asocia a Mejores Resultados tras una Intervención Periférica

Caitlin E. Cox

December 16, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

Six Months Sufficient for Dual Antiplatelet Therapy

Jason Kahn

October 17, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

Advertisement

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Aspirin as Standalone Stroke Protection Still Overused for Patients With A-fib

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Aspirin Hypersensitivity Can be Managed in PCI Patients Without Switching Drugs

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

Registro del CORONOR: Warfarin a Largo Plazo + Agente Antiplaquetario Aumenta las Hemorragias en Pacientes con EAC Estable

CORONOR Registry: Long-term Warfarin Plus Antiplatelet Increases Bleeding in Stable CAD Patients

Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD

High Reactivity on Aspirin Just Before PCI Linked to Worse Outcomes

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

El Control del Factor de Riesgo se asocia a Mejores Resultados tras una Intervención Periférica

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Six Months Sufficient for Dual Antiplatelet Therapy

Long-term Antiplatelet Therapy: All Risk, No Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content